Vakzine Projekt Management Gmbh v. Assistant Controller Of Patents And Designs

USV Private LimitedvsPaksons Pharmaceutical Pvt Ltd

The Delhi High Court granted an interim injunction in favor of USV Private Limited against Paksons Pharmaceutical Pvt Ltd, finding a prima facie case of trademark infringement and passing off. The court noted that the defendant's use of a deceptively similar mark for 'Multi Vitamin Infusion' could mislead consumers into believing the product originated from the plaintiff. Consequently, the defendant was restrained from using the infringing trademark until further hearing.

Ulink Agritech Private Ltd.vsSml Limited & Others

The appellant challenged an ex-parte ad-interim injunction granted by the Single Judge, which restrained them from infringing Patent No. 282092 (covering 'SELZIC'). The core legal issue was whether the Single Judge's order contained adequate reasons as mandated by proviso to Order 39 Rule 3 CPC. The High Court found that the conclusion of a prima facie case was not preceded by any proper reasoning, leading to the setting aside and remittance of the injunction.

Jagran Prakashan LtdvsJagran Production Ltd & Anr

The Delhi High Court addressed multiple connected suits involving Jagran Prakashan Ltd against various related entities concerning the use of the 'JAGRAN' trademark. The court noted significant changes, including a company name change and another entity being under liquidation. Given the lack of compliance with previous orders regarding business operations, the court granted an extended deadline for defendants to file affidavits detailing their current business activities. Furthermore, the parties were directed to explore mediation as a potential resolution pathway.

Bristol Myers Squibb CompanyvsDeputy Controller of Patents, Patent Office

Bristol Myers Squibb appealed the rejection of its patent application for a new hemisulphate salt of Compound (I), which was based on Section 3(d) of the Patents Act, 1970. The appellant argued that the compound demonstrated enhanced bioavailability and therapeutic efficacy compared to the free base form. The High Court set aside the rejection order and remanded the matter for reconsideration by a different officer.

Boehringer Ingelheim Pharma Gmbh And Co KgvsThe Controller Of Patents & Anr.

Boehringer Ingelheim Pharma challenged the rejection of its application seeking to quash a pre-grant opposition filed against its patent application. The petitioner argued that the opposition lacked reasonable justification, while the court addressed the issue of abuse of process under Section 25(1).